IL4R and asthma: Indeed, the European Academy of Allergy Asthma & Clinical Immunology (EAACI) position paper on clinically applicable biomarkers for asthma cites FeNO as the best biomarker to guide anti-IL4Rα-targeted (endotypic) therapy, which was evaluated following the SAVED approach (18).